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ABSTRACT
In non-Hodgkin lymphoma allogeneic stem cell transplantation (SCT) can be curative, but with standard dose
conditioning patients may have substantial morbidity and mortality from graft-versus-host disease (GVHD); for
aggressive malignancies, reduced intensity conditioning may result in higher recurrence. Patients with advanced
follicular lymphoma (n 12), transformed B cell malignancy (n 11), and non-CD30T cell lymphomas (n 17)
responsive to chemotherapy who had an HLA-identical sibling were offered T cell depleted (CAMPATH-1 G or
H antibodies) SCT. Conditioning was with ablative doses of chemotherapy or radiotherapy. Before SCT, patients
with follicular lymphoma had a median of 3 treatment courses, and those with transformed B cell and those
diagnosed with T cell non-Hodgkin lymphoma had 2 (range, 1-3). At SCT the median age was 46 years (range,
21-59 years) and the number of CD34 cells infused was 2.85  106/kg. All patients showed engraftment but
7 patients (17.5%) developed GVHD. In total 12 subjects expired of transplant-related causes (n  6) or from
disease recurrence. One-year transplant-related mortality was 15%. There was no difference in survival across
diagnostic groups. At a median of 1051 days, 70% survived and 68% are without disease. By reducing the incidence
and severity of GVHD, patients can tolerate myeloablative doses of chemotherapy satisfactorily. This has resulted
in low treatment-related mortality and adequate protection from disease recurrence.
© 2007 American Society for Blood and Marrow Transplantation
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Recent advances in the understanding of the biol-
gy of lymphoproliferative disorders have provided
hysicians with a more comprehensive therapeutic
rmamentarium and, at least for diffuse large B cell
ymphoma, have led to improvement in survival [1]. In
ow-grade non-Hodgkin lymphomas (NHLs) modern
trategies have also resulted in improvement in re-
ponses; however, a similar extension in survival still
ppears elusive [2]. Moreover, a proportion of patients
as follicular lymphomas that tend to progress to
istologically more aggressive forms, with particularly
oor outcome. Depending on whether postmortem
tudies are included, the incidence of this histologic
ransformation varies from 30%-40% to as high as
0%, with reported median overall survivals of about ryear [3-7]. Similarly, the management of T cell
alignancies remains largely unsatisfactory, particu-
arly for patients with lymphoblastic lymphoma and
ho present with extensive extranodal involvement or
one marrow inﬁltration and for those with peripheral
cell lymphomas. Although initially responsive, these
alignancies tend to have a recurring course [8].
Compared with standard chemotherapy, myeloa-
lative conditioning and stem cell support have been
ssociated with prolonged disease-free survival in se-
ected individuals with indolent malignancies and pe-
ipheral T cell lymphomas [9]. However, high disease
ecurrence rates after transplantation and secondary
ematologic complications precluded many patients
rom having signiﬁcant advantages in survival. In this
egard, the therapeutic beneﬁts of allogeneic grafting
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N. Novitzky and V. Thomas108ange from the antiproliferative actions of the dose-
ntense myeloablative conditioning to the putative
graft-versus-tumor” effect, often observed among pa-
ients who develop graft-versus-host disease (GVHD)
10,11]. This latter observation has been the basis of
ew strategies that induce powerful immunosuppres-
ion to favor engraftment, avoiding the side effects of
yeloablative doses of chemotherapy or radiation that
re particularly troublesome for older patients. How-
ver, GVHD may be protective against disease recur-
ence, it has been associated with high morbidity and
ubstantial mortality, especially from opportunistic in-
ections [12]. This has been particularly problematic
or those undergoing reduced intensity conditioning
ombinations and receiving unfractionated cytokine
obilized peripheral blood progenitor cell transplants
13,14].
T cell depletion of allogeneic stem cell grafts re-
ains the most effective strategy in the prevention of
VHD, although some loss of the graft-versus-tumor
ffect has been suggested. We previously reported that,
espite intense myeloablation, patients who received
rafts that had been incubated with CAMPATH “in the
ag” had low rates of GVHD, with low disease recur-
ence rates that transpired in good overall survival.
e also showed that these beneﬁcial effects were
articularly maintained in older patients, even up to
he age of 60 years [15,16]. We have now reviewed the
utcome of a group of patients with NHLs and show
hat myeloablative conditioning followed by infusion
f T cell-depleted grafts remains associated with fa-
orable long-term outcome.
ETHODS
This study included consecutive adults with NHL
ho received grafts between January 1990 and July
005 from their HLA-identical siblings. The histo-
ogic groups treated included advanced stage grade I
nd II follicular lymphomas, transformed lymphoma,
nd non-CD30 T cell malignancies. These groups
re considered to have a poor prognosis with standard
hemotherapy and their autologous stem cell trans-
lants frequently fail. For this population, entry crite-
ia included adequate performance status (0, 1, or 2),
onreactivity for human immunodeﬁciency virus test-
ng, and malignancy that was still sensitive to salvage
hemotherapy.
Individuals with indolent lymphomas were only
onsidered for this program after a second response to
lkylating agents, alone or in combination with vin-
ristine and prednisone [17], particularly if the malig-
ancy had progressed within 12 months of therapy.
ransformation of follicular lymphoma was deﬁned
n biopsy material of suitable quality as change in
istology to diffuse large cell lymphoma. Individuals with transformed NHL were typically treated ﬁrst
ith a combination containing cyclophosphamide,
aunorubicin, vincristine, and prednisone [18]. Pa-
ients with lymphoblastic lymphoma received as in-
uction weekly doses of vincristine (2 mg/m2), aspar-
ginase (10 000 U mg/m2), and daunorubicin (25
g/m2) and daily doses of prednisone (40 mg/m2) for
weeks. Those achieving remission received as con-
olidation 3 weekly chemotherapy courses. Before
ransplantation these patients received spinal prophy-
axis with cytarabine (20 mg) methotrexate (12 mg/m2),
nd dexamethasone (1 mg) [19]. Patients unresponsive
o or progressive on these combinations were rescued
ith platinum or high-dose cytarabine based pro-
rams (dexamethasone, high-dose cytarabine, and cis-
latin) [20]. Patients who on restaging were found to
ave responsive disease, deﬁned as50% reduction in
umor load, and had an HLA-identical sibling were
ffered allogeneic stem cell transplantation (SCT).
reparation for Transplantation
The routine management of our patients in prep-
ration for transplantation, transfusion strategy, and
ntibiotic policies have been previously described
15,16,21]. During the study period 2 myeloablative
onditioning protocols were used. One was radiother-
py based and the other consisted of cytotoxic agents
nly. The selection of the conditioning was derived
rom the availability of radiotherapy space in a busy
ertiary hospital oncology program. The radiation-
ased conditioning regimen was fractionated total
ody irradiation delivered in 6 twice-daily fractions of
Gy (total, 1200 cGy) and 4 fractions of total lym-
hoid irradiation of 1.5 Gy followed by cyclophosph-
mide 60 mg/kg (with mesna cover) on days 2 and
1 [14,16]. When radiotherapy was not available,
ndividuals received conditioning with oral busulfan
mg/kg  12, melphalan 70 mg/m2 on 2 consecutive
ays (total dose, 140 mg/m2), followed by cyclophos-
hamide 60 mg/kg on 2 consecutive days. Post-trans-
lantation patients received valacyclovir 1 g, 8 hourly,
or 3 months. After leukocyte recovery cytomegalovi-
us (CMV) reactivation was monitored by weekly
p65 determination. Reactivation of CMV was treated
ith ganciclovir 5 mg/kg twice daily for 14 days fol-
owed by ganciclovir 3 mg/kg daily or oral valganci-
lovir for 3 months.
ollection of Stem Cells for Transplantation
The details of our stem cell harvest protocols have
een published previously [15]. Brieﬂy, bone marrow
BM) for transplantation was collected under general
nesthesia by multiple needle aspirates. Mononuclear
ells were subsequently concentrated with an IBM
997 (Lakeside, Ill) or Cobe Spectra (Gambro, Lake-
ood, CO) apheresis units. Since October 1996, the
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Allogeneic Stem Cell Transplantation for Lymphoma 109ource of stem cells was cytokine (ﬁlgrastim, a gran-
locyte colony-stimulating factor [G-CSF], subcuta-
eous injections at 5-10 g/kg daily for 5 days) mo-
ilized peripheral blood progenitor cells (PBPCs)
rom HLA-identical siblings. Large-volume apheresis
as started approximately 4 hours after the last dose of
-CSF. During each procedure, approximately 30 L
f blood was processed. In the PBPC grafts, CD34
rogenitors were enumerated by ﬂow cytometry ac-
ording to guidelines of the International Society for
ematotherapy and Graft Engineering [22] using
hycoerythrin-labeled CD34 antibody and ﬂuorescein
sothiocyanate-labeled CD45 antibody and appropri-
te isotypic controls. Based on a patient’s ideal body
eight, the target cell dose was 5  108 mononu-
lear cells/kg or 2  106 CD34 cells/kg. In the event
hat the target cell dose was not achieved, apheresis
as repeated the following day. To conﬁrm engraft-
ent and to determine the origin of hematopoiesis,
ex chromosome differences between donor and re-
ipient were determined at 3 months after transplan-
ation by standard cytogenetic analysis of BM cells.
reatment with Monoclonal Antibody
CAMPATH-1G and CAMPATH-1H are di-
ected against CD52, a surface antigen that is present
n lymphocytes and monocytes [23]. CAMPATH-1H
as prepared from the culture supernatant of Chinese
amster ovary cell transfectants and subjected to a
nal puriﬁcation by size exclusion chromatography on
Superdex 200 (Therapeutic Antibody Centre, Ox-
ord, UK) [24]. Stem cell-rich products were then
reated with CAMPATH-1G (rat immunoglobulin G)
r CAMPATH-1H (humanized) and 1-2 mg of anti-
ody per 108 mononuclear cells was added in the bag,
llowed to react at 20°C for 30 minutes, and infused
ntravenously without any ﬁlters. According to the
ononuclear cell number in the transplant cell con-
entrate, the target dose of antibody was 7.5-45 mg.
In patients undergoing BM transplantation (BMT),
o further immunosuppression was provided after
MT. However, as in patients receiving PBPC grafts,
higher incidence of GVHD was observed; 7 patients
eceived prophylactic prednisone at 30 mg daily for 90
ays. In the remaining 19 patients, intravenous cyclo-
porin was commenced on day 1 and, upon recovery
f the gastrointestinal tract from the effects of the
onditioning, it was continued as an oral formulation
ntil day 90, while maintaining at all times therapeutic
lood levels (120-275 ng/mL) [15].
raft-versus-Host Disease
GVHD was deﬁned according to the Seattle cri-
eria [25]. Acute GVHD, grades II-IV, was treated
ith systemic prednisone (2-10 mg/kg daily) with or
ithout cyclosporin (10 mg/kg daily or according to llood levels). Once this phenomenon was controlled,
mmunosuppression was tapered off according to clin-
cal response.
tatistical Analysis
Chi-square statistic or Fisher exact tests were used
o establish differences in the distribution of discon-
inuous variables and Student t test to compare con-
inuous variables. All reported P values are 2-sided.
verall survival estimates were calculated from date of
ransplantation to date of death or last follow-up and
alculated by the Kaplan-Meier method; comparisons
ere made using the log-rank test. Disease-free sur-
ival was computed from time of transplantation to
eath or disease recurrence. Univariate and multivar-
ate analyses of variables predicting survival were per-
ormed using the log-rank test and the Cox model of
roportional hazards, respectively. Multifactorial non-
inear regression was used to analyze any relation
etween survival and the following covariates: type of
ymphoma, patient gender, patient age, antibody dose,
tem cell dose, and presentation International Prog-
ostic Index (IPI) scores. All data analyses were per-
ormed using Statistica (StatSoft Inc, Tulsa Okla).
ESULTS
Between 1990 and 2005, 40 consecutive patients
ave consent according to the guidelines of the Uni-
ersity of Cape Town and Groote Schuur Hospital to
ndergo transplantation with hematopoietic stem cells
rom HLA-identical sibling donors. Demographic de-
ails, source of stem cells, diagnoses of the malignancy,
istribution of disease groups, and outcome are pre-
ented in Tables 1 and 2.
In 10 patients the source of stem cells was the BM,
hereas 30 received ﬁlgrastim (G-CSF) mobilized pe-
ipheral blood grafts. Prophylaxis of GVHD was the
at anti-CD52 antibody CAMPATH-1G in the ﬁrst
2 patients, and the rest received PBPCs that had been
reated with CAMPATH-1H, a humanized antibody.
he median presentation corrected IPI score has been
n use from 1990 (before the follicular lymphoma IPI
26] score became available) and for the entire cohort
he score was 2 (range, 1-4). As presented in Table 1,
igh IPI score was signiﬁcantly associated with treat-
ent failure. Speciﬁc values for each histologic group
re presented in Table 2. There was no signiﬁcant
ifference in age at transplantation between patients
ndergoing BMT (median, 42.5; range, 29-55) or
BPC transplantation (median, 46; range, 17-59;
 .6) or between patients receiving the 2 antibody
ypes for T cell depletion. Fourteen (35%) patients
eceived chemotherapy-based conditioning, whereas
nother 26 patients were conditioned with myeloab-
ative radiotherapy. At transplantation their respective
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N. Novitzky and V. Thomas110edian ages were 42 years (range, 17-59 years) and
6.5 years (range, 17-62 years; P  .2). Median fol-
ow-up was 1051 days (range, 16-5598 days), with
2% and 71% surviving. There was no difference in
urvival between the 2 conditioning groups (P  .15).
ngraftment and Treatment-related Mortality
Graft characteristics are listed in Table 1 (also see
able 2). Although the median granulocyte-macroph-
ge colony-forming units  104/kg was lower in the
M group (14.3 versus 27.9; P .4) than in the PBPC
roup, this difference was not signiﬁcant. Results of
D34 count were available in 26 collections. The
edian value was 2.85  106/kg (range, 1.31-8.4).
xcept for 1 patient who died of a fungal infection on
ay 15, all patients recovered their blood parameters
fter graft infusion. Median time to a granulocyte
ount 0.5  109/L and platelet count 50  109/L
as 13 days (range, 9-35 days) and was not signiﬁ-
antly different between the BMT and PBSC groups.
eventeen patients received a stem cell graft from an
pposite-gender donor. A karyotypic analysis of their
arrow cells showed full donor chimerism in each
ase. Seven (18%) patients developed GVHD (grade
I). Reactivation of CMV was seen in 7 (18%) pa-
ients; 5 by a positive pp65 test and 2 after colonos-
opy and intestinal biopsy showing CMV colitis. All
atients responded to ganciclovir.
able 1. Clinical and Laboratory Parameters of Stem Cell Grafts and
All Patients (n
BI/chemotherapy conditioning 26/14
PI score, median (range) 2 (1-4)
tem cell source, BM/PBSC 10/30
D34  106/kg, median (range) 2.85 (1.31-6
M-CFU  104/kg, median (range) 23.6 (2.78-3
AMPATH-1G/1H 12/28
AMPATH-1G/1H dose, median (range) 12.5 (7.5-45
VHD (%) 7 (18%)
elapse (%) 7 (16%)
BI indicates total body irradiation; IPI, International Prognostic
granulocyte-macrophage colony-forming unit; GVHD, graft-ve
able 2. Clinical Characteristics and Outcomes according to Histologic G
Follicular NHL
(n  12)
Tran
ge, median (range) 47.5 (21-57) 4
PI score median, range 3 (2-4)
umber of treatment courses,
median (range) 4 (2-8)
RM 2/12
elapsed 1/12
S (%) 75%
FS, median (range) 777 (92-4401) 164
HL indicates non-Hodgkin lymphoma; IPI, International Progno
disease-free survival.P  .001.Twelve patients died, 6 of disease recurrence, 1 of
efractory hepatic GVHD, and 5 of infections (Candida
lbicans, Pneumocystis carinii, pneumococcal meningitis,
ultilobar pneumonia), 4 after steroid treatment for
linically relevant GVHD. One patient died of liver
ailure from progressive hepatic GVHD despite therapy
ith high-dose steroids, tacrolimus, and azathioprine.
ne patient developed disease recurrence and is cur-
ently receiving donor lymphocyte infusions. Median
ime to death of the 12 patients was 265 days (range,
6-3863 days) and only 3 died 1000 days after transplan-
ation. Overall, after transplantation, 70% survived at a
edian of 1719 days (range, 111-5039 days; Figure 1).
Of the various factors analyzed, age-corrected IPI
2 versus 2, P  .03) and occurrence of GVHD
P .001) were signiﬁcant adverse factors for survival.
roportional hazards (Cox) regression analysis con-
rmed that only absence of GVHD signiﬁcantly pre-
icted a favorable outcome (P  .001; Figure 2).
urvival According to Diagnosis
Transplantation was prescribed for the following
istologic groups: follicular (grade I, 33%; grade II,
7%) in 12 individuals, transformed large cell in 11,
ymphoblastic in 8, and peripheral T cell in 9 (Figure 3,
able 2). Patients receiving grafts for follicular lym-
homa had undergone a median of 3 treatment mo-
alities (range, 2-7) before being referred for trans-
of Patient Mortality
Alive (n  28) Dead (n  12) P
16/12 10/2 .08
2 (1-3) 3 (1-4) .04
7/21 3/9 NS
2.92 (1.8-6.2) 2.22 (1.47-3.76) .4
17.8 (10.4-379) 30.6 (2.28-63.1) .5
8/20 4/8 .8
10 (7.5-35) 20 (10-45) .05
1 (14%) 6 (86%) <.001
1 6 (50%)
BM, bone marrow; PBSC, peripheral blood stem cell; GM-CFU,
st disease.
n Patients Undergoing Stem Cell Transplantation
d NHL
1)
T Cell NHL
(n  9)
Lymphoblastic Lymphoma
(n  8)
5) 42 (29-59) 31.5 (18-47)*
2 (1-4) 3 (2-4)
2 (2-5) 1 (1-2)
2/9 0/8
1/9 3/8
78% 63%
4398) 1226 (145-4107) 2970 (95-4954)
ex; TRM, transplant-related mortality; OS, overall survival; DFS,Causes
 40)
.2)
79)
)
Index;roup i
sforme
(n  1
8 (38-5
2 (2-4)
2 (1-3)
2/11
2/11
64%
6 (568-
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Allogeneic Stem Cell Transplantation for Lymphoma 111lantation. Their median age-adjusted IPI score on
rst admission was 2 (range, 1-3).
All patients with lymphoblastic lymphoma had ex-
ensive disease at presentation, including bulky (n 4)
nd extranodal (n  4) malignancies or inﬁltration of
M (n  3) by lymphoma; all these ﬁndings are asso-
iated with poor prognosis with standard therapies.
hese patients underwent transplantation in complete
emission (1  3) and the median performance status
as 1 (range, 1-2). Individuals with peripheral T cell
alignancies received grafts in ﬁrst complete remission
Died  
0 500 1000 1500 2000 2
Follow 
0.0
0.2
0.4
0.6
0.8
1.0
C
um
ul
at
iv
e 
Pr
op
or
tio
n 
Su
rv
iv
in
g
igure 1. Disease-free survival (DFS) and overall survival (OS) for
rafts depleted of lymphocytes by CAMPATH-1G or 1H.
Died  
0 500 1000 1500 2000 2500
Time
0.0
0.2
0.4
0.6
0.8
1.0
C
um
ul
at
iv
e 
P
ro
po
rti
on
 S
ur
vi
vi
ng
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ifference is statistically signiﬁcant with log-rank test.n  5) or in subsequent responses after various salvage
herapies. After graft infusion 2 died, 1 of fungal sepsis
nd the other of unresponsive hepatic GVHD.
After transplantation, relapse was seen in 8% of
ollicular, 18% of transformed, 11% of peripheral T
ell, and 37% of lymphoblastic histology. As seen in
igure 3, Kaplan-Meier analysis showed no signiﬁcant
ifference in survival in any of the 4 diagnostic groups.
oreover, log-rank analysis failed to conﬁrm that
resentation IPI inﬂuenced survival after transplanta-
ion (IPI 0  1  2 versus 2; P  .17; data not
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s)
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N. Novitzky and V. Thomas112hown). At the time of this analysis, median follow-up
as 1051 days (range, 15-5039 days) and 27 patients
68%) survived without disease.
ource of Stem Cell Grafts, T Cell Depletion,
nd GVHD
CAMPATH-1G was employed in 10 patients who
eceived BM and in 2 who had PBPC grafts, and the
emainder received PBPC products treated with
AMPATH-1H (Table 2). For ex vivo treatment of
rafts, the median dose of CAMPATH-1H employed
as 13.75 mg (range, 10-40 mg), which was higher in
he BMT group (20 mg; range, 10-30 mg) than in the
BPC group (median, 10 mg; range, 7.5-30 mg; P 
05). In total 7 patients developed acute or chronic
VHD, but none developed the hyperacute forms of
his complication. None of the patients whose stem
ells were treated with CAMPATH-1G received post-
ransplantation immunosuppression. From this group,
of 10 patients who received BM transplants devel-
ped grade II acute GVHD but this did not progress
o the chronic form. Because all 3 patients who re-
eived PBPC grafts purged with CAMPATH-1H and
ad no further immunosuppression developed aggres-
ive but corticosteroid-responsive GVHD (grade II),
ost-transplantation prednisone 30 mg/day or cyclo-
porin for 90-120 days was prescribed for the last 7
nd 20 individuals, respectively. After this protocol
mendment, only 2 subjects (P  .06) and 1 subject
P  .001), respectively, developed this complication.
he corresponding survivals among patients receiving
rafts that had been treated with CAMPATH-1G or
H were 64% and 72% (P .2), but increased to 84%
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ransformed NHL.n those who received cyclosporin. 4After engraftment, acute GVHD grade II was
etected in 7 patients (grade II in 6; grade IV in 1),
nd 3 developed the chronic form (1 extensive chronic
VHD); all progressed from the acute presentation.
hree patients died of infection while receiving treat-
ent with corticosteroids and cyclosporin for symp-
omatic GVHD. Another who had no evidence of
VHD also died of infection while still on treatment
ith immunosuppressive therapy. Two individuals
ith clinical features of GVHD had disease recur-
ence and died of lymphoma despite salvage therapy.
or the entire study group, the 2-year survival was
7%.
As part of another study, immune reconstitution
nalysis was done in 11 patients [27]. It showed rapid
ecovery of the CD8 and CD56 lymphocytes but
igniﬁcant delay in recovery of the CD3/CD45RA
nd CD4/CD45RA (naive) population, with nor-
alization of all parameters by 18 months after trans-
lantation (data not shown).
Although overall no signiﬁcant difference in sur-
ival between the 2 antibody-treated groups was elic-
ted, in univariate analysis the survival was signiﬁ-
antly associated with a lower (than median) dose of
AMPATH-1, lower presentation IPI score (IPI 
 1), absence of clinically relevant GVHD, and
ost-transplantation treatment with cyclosporin (sur-
iving 84%; P  .05). Cox logistic regression analysis
onﬁrmed that only occurrence of GVHD remained
igniﬁcantly associated with worse outcome (Figure 2;
 .001). Median follow-up exceeded 3 years in 20
atients, and at median of 2610 days (range, 1120-
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Allogeneic Stem Cell Transplantation for Lymphoma 113homa (n  2) and infection (associated with chronic
VHD).
oxicity
All patients developed grade IV hematologic tox-
city and required transfusion support with red cells
nd platelets. Pyrexia requiring intravenous antibiotics
as seen in 89% of patients and 1 died of unresponsive
albicans sepsis. Radiotherapy-based conditioning was
ell tolerated and only 15% of patients (2 in BMT
roup and 4 in PBPC group) developed gastrointes-
inal toxicity of grade 2 according to the World
ealth Organization. In the chemotherapy-condi-
ioning cohort, 4 patients developed grade 2 mu-
ositis. One patient developed fatal GVHD of the
iver.
ISCUSSION
Indolent NHLs are associated with favorable re-
ponses to various forms of chemotherapy and biolog-
cal cell modiﬁers, but with conventional chemother-
py these diseases tend to recur and remain incurable.
urther, despite modern salvage therapy, patients with
ollicular morphology who develop histologic trans-
ormation or have refractory disease have poor out-
ome and generally die of their malignancy within 1
ear [3,4,28]. In an attempt to improve responses,
nvestigators have applied myeloablative conditioning
ollowed by autologous SCT and have shown that
hese lymphomas are generally sensitive to such intensi-
ed chemotherapy [9,10,28,29]. However, in patients
ith indolent NHL treated with SCT, a persistent
endency for disease recurrence has been observed
30,31]. In addition, a proportion of patients devel-
ped myelodysplastic syndromes and acute leukemia,
robably secondary to extensive exposure to cytotoxic
hemotherapy, and therefore no convincing improve-
ent in survival has been demonstrated with this mo-
ality. Similarly, patients with T cell lineage (non-
D30) lymphoma may initially be responsive to
herapy but have high recurrence rate, and with con-
entional cytotoxic therapy their diseases have mainly
emained incurable [8]. In this regard, lymphoblastic
ymphoma is also highly responsive to chemotherapy;
owever, those who on presentation have extranodal
isease, high disease bulk, or BM inﬁltration have less
ood outcome [8].
Allogeneic SCT has curative potential in patients
ith hematologic malignancies, particularly if patients
ave remained responsive to chemotherapy [10,28,29].
owever, patients with lymphoproliferative disorders
re older and may have already undergone autologous
CT, thus explaining the higher morbidity and mor-
ality of the high-dose conditioning and particularly
rom GVHD. In another study, the incidence of mVHD (grade II-IV) in such patients was 55%, lead-
ng to 100-day mortality of 34%, although the overall
urvival was 45% [29,30]. Only at 6 years did the
urvival curves of autologously and allogeneically
ransplanted patients cross, with continuing relapses
bserved in the autologous group [30]. For this rea-
on, less toxic conditioning schedules have been de-
cribed that are mainly immunosuppressive and result
n good engraftment rates with low toxicity-related
ortality [14,32]. However, such combinations have
een less successful in preventing malignant recur-
ence in patients with refractory or transformed lym-
homas [33].
The role of myeloablative conditioning and trans-
lantation in lymphoma has been better clariﬁed by
ierman et al [29] who compared the outcome of
atients receiving autologous, unfractionated alloge-
eic, T cell-depleted, and syngeneic stem cell grafts
fter myeloablative conditioning. There was no differ-
nce in relapse across the 3 forms of allogeneic SCT,
uggesting that the graft-versus-lymphoma effect was
ot very different among the 3 sources of stem cells.
his implied that absence of malignant cells from the
raft in the allogeneic source had greater importance
han the immunologic effect of transplantation. This
as also been our experience with T cell depletion
ith CAMPAT-1H antibodies.
Lymphocyte purging of the graft remains the most
ffective strategy for the prevention of GVHD [34].
lthough concerns have been raised regarding loss
f the graft-versus-tumor effect, we recently found
hat in patient receiving grafts treated ex vivo with
AMPATH-1H and after transplantation with cy-
losporin for 90 days, the disease relapse and treat-
ent-related mortality rates were low, which resulted
n good overall survival. Moreover, there was no dif-
erence in outcome between young and older patients,
uggesting that this modality could be used up to the
ge of 60 years [16]. An important cause of mortality
as infection, which even after hematopoietic recov-
ry, led to recurrent admissions. It was the main cause
f death in patients developing GVHD. Although in a
revious study we reported delayed immune reconsti-
ution, in the present study it did not lead to increased
eactivation of CMV [27]. Overall, 8 individuals de-
eloped disease recurrence, at a median of 6.5 months.
he 40-month event-free and overall survival rates
ere estimated at 54% and 59%, respectively (Figure
). In the present study, patients with recurrent but
till chemotherapy-sensitive follicular disease did par-
icularly well (Figure 3) and only 1 patient relapsed. A
imilar experience was reported by Mandigers et al
35]. Particularly encouraging was the outcome of
atients with transformed lymphoma because with
tandard approaches survival seldom exceeds 18
onths. Although peripheral T cell lymphomas re-
ain mostly incurable with standard chemotherapy
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N. Novitzky and V. Thomas114nd even with high-dose therapy outcomes remain
oor [36], in the present series their long-term
isease-free survival remained at 78%. One strength
f studies with conventional conditioning is the
emonstration of very few late relapses, a feature
hat has yet to be conﬁrmed in the majority of
atients receiving reduced intensity conditioning
chedules.
It may be argued that our patient cohort had a
ore favorable prognosis because none had under-
one a previous SCT; however, all had advanced dis-
ase as evidenced by multiple courses of chemother-
py before transplantation or had aggressive histology.
n our series, the median survival for the entire group
as not been reached, and at a median follow-up of
501 days 70% are alive (1 responding to donor lym-
hocyte infusion) and 68% are in response. This en-
ouraging outcome in this group of lymphomas is
uggestive that, when the procedure-related mortality
s low, the strategy of earlier transplantation, before
isease becomes refractory to salvage therapy, is ap-
ropriate and should be strongly considered.
In conclusion, this study reinforces our previous
bservations that allogeneic SCT with standard con-
itioning leads to adequate clearance of the disease
nd is well tolerated in the absence of GVHD. In our
xperience the prevention of clinically relevant
VHD has resulted in a signiﬁcantly better outcome
Figures 1 and 3) and a better overall survival [15,16].
s previously described in another study in patients
eceiving autologous, syngeneic, and allogeneic T
ell-depleted transplants for NHL, this latter strategy
as also associated with a low recurrence rate in the
ong term [29]. However, only a randomized trial of
dequate statistical power comparing well-deﬁned
roups of patients receiving reduced intensity condi-
ioning or myeloablative approaches (with unfraction-
ted or T cell-depleted grafts) can clearly show the
ole of each approach. Until such studies are com-
leted, although patients with follicular lymphoma
ay be treated with either modality, those with
ransformed lymphoma and with T cell disease
hould be considered candidates for myeloablative
onditioning.
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